

## 1

7. ☒ The specification has been updated to reflect the following information:

--This application is a ☐ continuation ☒ division of application Serial No. 10/241,927, filed September 11, 2002, now pending, which is a continuation of application Serial No. 09/444,027, filed November 19, 1999, now abandoned, which is a continuation-in-part of application Serial No. 09/154,903, filed September 17, 1998, now abandoned, which is a continuation-in-part of application Serial No. 08/725,540, filed October 3, 1996; now abandoned, which is a continuation-in-part of application Serial No. 08/539,142, filed October 4, 1995, which are hereby incorporated by reference.--

8. ☐ Transfer the drawings from the prior application to this application and abandon said prior application as of the filing date accorded this application. A duplicate copy of this sheet is enclosed for filing in the prior application file. (May only be used if signed by person authorized by § 1.138 and before payment of base issue fee.)

8a. ☐ New formal drawings are enclosed.

9. ☐ Priority of application Serial No. \_\_\_\_\_ filed on \_\_\_\_\_ in \_\_\_\_\_ (country) is claimed under 35 USC 119.

9a. ☐ The certified copy has been filed in prior application Serial No. \_\_\_\_\_ filed \_\_\_\_\_

10. ☐ The prior application is assigned of record to Immunex Corporation


11. ☐ A preliminary amendment is enclosed.

12. ☒ Also enclosed Statement Under 37 CFR §1.125; Postcard

13. ☐ Other: \_\_\_\_\_

Address all future communications to

James E. Klaniecki  
at the address below.

  
James E. Klaniecki  
Attorney/Agent for Applicants  
Registration No. 38,207  
Phone: (206) 265-4145  
Date: August 19, 2003

Please send all future correspondence to:

Immunex Corporation  
Law Department  
51 University Street  
Seattle, WA 98101  
(206) 587-0430  
eh141002 8/19/03

**22932**  
PATENT TRADEMARK OFFICE

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the Application of:

Kenneth A. Brasel, Stewart D. Lyman,  
Eugene Maraskovsky, Hilary J. McKenna  
and David H. Lynch

Docket No.: 2836-H

Group Art Unit: Unknown

Serial No: --to be assigned--  
Divisional of USSN 10/241,927

Prior Application:  
Examiner: P. Gambel

Filed: August 19, 2003

For: **THE USE OF FLT3-LIGAND IN THE TREATMENT OF INFECTION**

MAIL STOP PATENT APPLICATION


Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**STATEMENT UNDER 37 CFR §1.125**

Applicants' representative attests that the amendatory material added to the substitute specification for the divisional application of U.S. Patent Application Serial No. 10/241,927 does not constitute new matter. The parent application (i.e., U.S. Patent Application Serial No. 10/241,927) of the presently filed application had incorporated U.S. Patent No. 5,554,512 by reference in its entirety. The amendatory material added to the substitute specification consists of essentially the same material as described in U.S. Patent No. 5,554,512. In addition, a sequence listing has been added to the substitute specification, which had been disclosed in U.S. Patent No. 5,554,512.



James E. Klaniecki  
Registration No. 38,207

Date: August 19, 2003

Immunex Corporation  
Law Department  
51 University Street  
Seattle, Washington 98101  
Ph. (206) 265-4145  
Fax (206) 233-0644